SCHEMBL19686319

SCHEMBL19686319

Cc1cc(C)n(-c2cc(OCc3ncnn3C)cc(NC3CCC(F)(F)CC3)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 1/20 0.38
KCNN3 Q9UGI6 1/20 0.38
GABRA1 P14867 4/20 0.33
GABRG2 P18507 4/20 0.33
GABRB3 P28472 4/20 0.33
GABRA3 P34903 4/20 0.33
GABRA5 P31644 1/20 0.33
SLC34A1 Q06495 11/20 0.33
GABRA2 P47869 3/20 0.32
NR2F2 P24468 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
S1PR2 O95136 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
XBP1 P17861 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686731 0.85 IDH1 (0.33) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL19687266 0.85 KCNN2 (0.39) KCNN2KCNN3GABRA1GABRG2GABRB3
SCHEMBL31127224 0.84 KCNN2 (0.46) KCNN2KCNN3GABRA1GABRG2GABRB3
SCHEMBL19686621 0.84 KCNN2 (0.38) KCNN2KCNN3NR2F2NPSR1KDM4E
SCHEMBL19686322 0.84 KCNN2 (0.46) KCNN2KCNN3GABRA1GABRG2GABRB3
SCHEMBL19686633 0.84 KCNN2 (0.37) KCNN2KCNN3SLC34A1NR2F2NPSR1
SCHEMBL19686628 0.82 ALDH1A1 (0.42) KCNN2KCNN3SLC34A1ALDH1A1
SCHEMBL19686882 0.82 KCNN2 (0.37) KCNN2KCNN3NR2F2NPSR1KDM4E
SCHEMBL19686886 0.82 PDE2A (0.42) KCNN2KCNN3SLC34A1NR2F2NPSR1
SCHEMBL21165991 0.81 KCNN2 (0.46) KCNN2KCNN3SLC34A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885GABRA1 325/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885GABRA1 325/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KCNN2 5/4885KCNN3 11/4885GABRA1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.